Patterns and determinants of COPD-related healthcare utilization by severity of airway obstruction in Korea

BMC Pulmonary Medicine

Volumn 14, Issue 1, 2014, Pages

  Chung, Kyungsoo ^a   Kim, Kyungjoo ^b   Jung, Jiye ^a   Oh, Kyungwon ^c   Oh, Yeonmok ^d   Kim, Sekyu ^a   Kim, Jinhee ^e   Kim, Youngsam ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yuhan Research Institute   (South Korea)

^c Korea Centers for Disease Control and Prevention   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

^e Chosun University   (South Korea)

Author keywords

Chronic obstructive lung disease; Healthcare use; Korean National Health and Nutritional Examination Survey; National health insurance claims

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; THEOPHYLLINE;

ADULT; AGE DISTRIBUTION; AGED; AIRFLOW; AIRWAY OBSTRUCTION; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CORTICOSTEROID THERAPY; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HEALTH SERVICE; HEALTH STATUS INDICATOR; HEALTH SURVEY; HOSPITAL PATIENT; HUMAN; KOREA; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NATIONAL HEALTH INSURANCE; OUTPATIENT; RETROSPECTIVE STUDY; SELF REPORT;

ADULT; AGED; AIRWAY OBSTRUCTION; FEMALE; HEALTH SERVICES; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84896733023     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-14-27     Document Type: Article

References (37)

1. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet 2012, 379(9823):1341-1351. 10.1016/S0140-6736(11)60968-9, 22314182.
2. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007, 370(9589):765-773. 10.1016/S0140-6736(07)61380-4, 17765526.
3. Tan WC, Ng TP. COPD in Asia: where East meets West. Chest 2008, 133(2):517-527. 10.1378/chest.07-1131, 18252918.
4. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summary. Am J Respir Crit Care Med 2012, 187(4):347-365.
5. Bednarek M, Maciejewski J, Wozniak M, Kuca P, Zielinski J. Prevalence, severity and underdiagnosis of COPD in the primary care setting. Thorax 2008, 63(5):402-407. 10.1136/thx.2007.085456, 18234906.
6. Soriano JB, Maier WC, Egger P, Visick G, Thakrar B, Sykes J, Pride NB. Recent trends in physician diagnosed COPD in women and men in the UK. Thorax 2000, 55(9):789-794. 10.1136/thorax.55.9.789, 1745847, 10950900.
7. Chapman KR. Chronic obstructive pulmonary disease: are women more susceptible than men?. Clin Chest Med 2004, 25(2):331-341. 10.1016/j.ccm.2004.01.003, 15099893.
8. Pena VS, Miravitlles M, Gabriel R, Jimenez-Ruiz CA, Villasante C, Masa JF, Viejo JL, Fernandez-Fau L. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest 2000, 118(4):981-989. 10.1378/chest.118.4.981, 11035667.
9. Centers for Disease C, Prevention Chronic obstructive pulmonary disease and associated health-care resource use - North Carolina, 2007 and 2009. MMWR 2012, 61(8):143-146. Centers for Disease C, Prevention.
10. Fitch K, Iwasaki K, Pyenson B, Plauschinat C, Zhang J. Variation in adherence with global initiative for chronic obstructive lung disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis. Curr Med Res Opin 2011, 27(7):1425-1429. 10.1185/03007995.2011.583230, 21599554.
11. Joo MJ, Lee TA, Bartle B, van de Graaff WB, Weiss KB. Patterns of healthcare utilization by COPD severity: a pilot study. Lung 2008, 186(5):307-312. 10.1007/s00408-008-9095-5, 18463921.
12. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, Maclntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J. Interpretative strategies for lung function tests. Eur Respir J 2005, 26(5):948-968. 10.1183/09031936.05.00035205, 16264058.
13. Mapel DW, Dutro MP, Marton JP, Woodruff K, Make B. Identifying and characterizing COPD patients in US managed care. A retrospective, cross-sectional analysis of administrative claims data. BMC Health Serv Res 2011, 11:43. 10.1186/1472-6963-11-43, 3050697, 21345188.
14. Blanchette CM, Broder M, Ory C, Chang E, Akazawa M, Dalal AA. Cost and utilization of COPD and asthma among insured adults in the US. Curr Med Res Opin 2009, 25(6):1385-1392. 10.1185/03007990902875927, 19419342.
15. Jung JY, Kang YA, Park MS, Oh YM, Park EC, Kim HR, Lee SD, Kim SK, Chang J, Kim YS. Chronic obstructive lung disease-related health care utilisation in Korean adults with obstructive lung disease. Int J Tuberc Lung Dis 2011, 15(6):824-829. 10.5588/ijtld.10.0432, 21575306.
16. Mapel DW, McMillan GP, Frost FJ, Hurley JS, Picchi MA, Lydick E, Spencer MD. Predicting the costs of managing patients with chronic obstructive pulmonary disease. Resp Med 2005, 99(10):1325-1333.
17. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006, 28(3):523-532. 10.1183/09031936.06.00124605, 16611654.
18. Menezes AM, Perez-Padilla R, Jardim JR, Muino A, Lopez MV, Valdivia G, de Oca Montes M, Talamo C, Hallal PC, Victora CG, PLATINO Team Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005, 366(9500):1875-1881. 10.1016/S0140-6736(05)67632-5, 16310554, PLATINO Team.
19. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Moqilnicka E, BOLD Collaborative Research Group International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007, 370(9589):741-750. 10.1016/S0140-6736(07)61377-4, 17765523, BOLD Collaborative Research Group.
20. Coultas DB, Mapel D, Gagnon R, Lydick E. The health impact of undiagnosed airflow obstruction in a national sample of United States adults. Am J Respir Crit Care Med 2001, 164(3):372-377. 10.1164/ajrccm.164.3.2004029, 11500335.
21. Glaab T, Banik N, Rutschmann OT, Wencker M. National survey of guideline-compliant COPD management among pneumologists and primary care physicians. Copd 2006, 3(3):141-148. 10.1080/15412550600829299, 17240616.
22. Decramer M, Bartsch P, Pauwels R, Yernault JC. Management of COPD according to guidelines. A national survey among Belgian physicians. Monaldi Arch Chest Dis 2003, 59(1):62-80.
23. Cooke CE, Sidel M, Belletti DA, Fuhlbrigge AL. Review: clinical inertia in the management of chronic obstructive pulmonary disease. Copd 2012, 9(1):73-80. 10.3109/15412555.2011.631957, 22292599.
24. Mapel DW, Picchi MA, Hurley JS, Frost FJ, Petersen HV, Mapel VM, Coultas DB. Utilization in COPD: patient characteristics and diagnostic evaluation. Chest 2000, 117(5 Suppl 2):346S-353S.
25. Soriano JB, Zielinski J, Price D. Screening for and early detection of chronic obstructive pulmonary disease. Lancet 2009, 374(9691):721-732. 10.1016/S0140-6736(09)61290-3, 19716965.
26. Kim DS, Kim YS, Jung KS, Chang JH, Lim CM, Lee JH, Uh ST, Shim JJ, Lew WJ, Korean Academy of Tuberculosis and Respiratory Diseases Prevalence of chronic obstructive pulmonary disease in Korea: a population-based spirometry survey. Am J Respir Crit Care Med 2005, 172(7):842-847. 10.1164/rccm.200502-259OC, 15976382, Korean Academy of Tuberculosis and Respiratory Diseases.
27. Han MK, Kim MG, Mardon R, Renner P, Sullivan S, Diette GB, Martinez FJ. Spirometry utilization for COPD: how do we measure up?. Chest 2007, 132(2):403-409. 10.1378/chest.06-2846, 17550936.
28. Heffner JE, Ellis R. The guideline approach to chronic obstructive pulmonary disease: how effective?. Respir Care 2003, 48(12):1257-1266. discussion 1267-1258.
29. Seaman J, Leonard AC, Panos RJ. Health care utilization history, GOLD guidelines, and respiratory medication prescriptions in patients with COPD. Int J Chron Obstruct Pulmon Dis 2010, 5:89-97. 2865029, 20463890.
30. Barr RG, Celli BR, Martinez FJ, Ries AL, Rennard SI, Reilly JJ, Sciurba FC, Thomashow BM, Wise RA. Physician and patient perceptions in COPD: the COPD resource network needs assessment survey. Am J Med 2005, 118(12):1415.
31. Park MJ, Choi CW, Kim SJ, Kim YK, Lee SY, Kang KH, Shin KC, Lee KH, Lee JH, Kim YI, Lim SC, Park YB, Jung KS, Kim TH, Shin DH, Yoo JH. Survey of COPD management among the primary care physicians in Korea. Tuberc Respir Dis 2008, 64(2):109-124.
32. Simon-Tuval T, Scharf SM, Maimon N, Bernhard-Scharf BJ, Reuveni H, Tarasiuk A. Determinants of elevated healthcare utilization in patients with COPD. Respir Res 2011, 12:7. 10.1186/1465-9921-12-7, 3032684, 21232087.
33. Vestbo J, Rasmussen FV. Respiratory symptoms and FEV1 as predictors of hospitalization and medication in the following 12 years due to respiratory disease. Eur Respir J 1989, 2(8):710-715.
34. O'Reilly JF, Williams AE, Holt K, Rice L. Defining COPD exacerbations: impact on estimation of incidence and burden in primary care. Prim Care Respir J 2006, 15(6):346-353. 10.1016/j.pcrj.2006.08.009, 17064963.
35. Hilleman DE, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. Chest 2000, 118(5):1278-1285. 10.1378/chest.118.5.1278, 11083675.
36. Hardie JA, Buist AS, Vollmer WM, Ellingsen I, Bakke PS, Morkve O. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J 2002, 20(5):1117-1122. 10.1183/09031936.02.00023202, 12449163.
37. Hanania NA, Mannino DM, Yawn BP, Mapel DW, Martinez FJ, Donohue JF, Kosinski M, Rendas-Baum R, Mintz M, Samuels S, Jhingran P, Dalal AA. Predicting risk of airflow obstruction in primary care: validation of the lung function questionnaire (LFQ). Resp Med 2010, 104(8):1160-1170.